{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001430023,0.0003290381,0.00140745,0.0002591354,0.00006861582,0.0000121293,0.00005420106,0.0001308659,0.000052124],"category_scores_gemma":[0.00001761806,0.0001631495,0.00007263575,0.0004293298,0.0001536745,0.0000575117,0.000003907043,0.0001156938,4.181811e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001001201,"about_ca_system_score_gemma":0.001889789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002638254,"about_ca_topic_score_gemma":0.002004161,"domain_scores_codex":[0.998441,0.0001891405,0.0006282583,0.0003501008,0.0001779676,0.0002135127],"domain_scores_gemma":[0.9981377,0.0006953949,0.0006344875,0.0002073859,0.0002801986,0.00004483882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01257394,0.00160972,0.0002907618,0.00761174,0.001273204,0.00002577778,0.001646684,0.00005229401,0.00001220758,0.00008230214,0.00007844187,0.9747429],"study_design_scores_gemma":[0.08790901,0.05859505,0.004569127,0.01455463,0.006805617,0.00003849417,0.0003842794,0.0002192822,0.0001932469,0.0001775547,0.8258963,0.0006574315],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00774233,0.9787567,0.0004829609,0.000416933,0.0001343226,0.01171355,0.0007022199,0.00002457629,0.00002641558],"genre_scores_gemma":[0.001882721,0.986869,0.001859237,0.0001107762,0.00002712964,0.00795483,0.0008690401,0.00004726596,0.0003800399],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9740855,"threshold_uncertainty_score":0.6653043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04601313563003731,"score_gpt":0.3846335911876247,"score_spread":0.3386204555575874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}